These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6997309)

  • 1. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
    Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
    J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of prostacyclin: formation of an active metabolite in the liver.
    Wong PY; Lee WH; Quilley CP; McGiff JC
    Fed Proc; 1981 May; 40(7):2001-4. PubMed ID: 7014260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin.
    McGiff JC; Spokas EG; Wong PY
    Br J Pharmacol; 1982 Jan; 75(1):137-44. PubMed ID: 7042021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and partial characterization of prostaglandin D2 11-keto reductase in rabbit liver.
    Wong PY
    Biochim Biophys Acta; 1981 May; 659(1):169-78. PubMed ID: 7248317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.
    Quilley CP; McGiff JC; Lee WH; Sun FF; Wong PY
    Hypertension; 1980; 2(4):524-8. PubMed ID: 6995292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the prostacyclin products, 6-keto prostaglandin E1 and 6-keto prostaglandin F1 alpha, on bone resorption in vitro.
    Neuman SD; Raisz LG
    Prostaglandins Leukot Med; 1984 Jul; 15(1):103-8. PubMed ID: 6382342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An NADP-linked prostacyclin dehydrogenase in rabbit kidney.
    Korff JM; Jarabak J
    Prostaglandins; 1981 May; 21(5):719-25. PubMed ID: 7041194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of 6-keto prostaglandin E1 in mammalian kidneys.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 May; 79(1):149-55. PubMed ID: 6347300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin releasing polymers - stability and efficacy.
    McRea JC; Ebert CD; Kim SW
    Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of prostaglandin I2 in human blood.
    Pifer DD; Cagen LM; Chesney CM
    Prostaglandins; 1981 Feb; 21(2):165-75. PubMed ID: 7012932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination from the circulation of cats of 6-keto-prostaglandin E1 compared with prostaglandins E2 and I2.
    Förstermann U; Neufang B
    J Pharm Pharmacol; 1983 Nov; 35(11):724-8. PubMed ID: 6139453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells.
    Oliva D; Bernini F; Corsini A; Nicosia S
    Biochem Pharmacol; 1984 Dec; 33(23):3755-8. PubMed ID: 6391491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets.
    Eggerman TL; Andersen NH; Robertson RP
    J Pharmacol Exp Ther; 1986 Mar; 236(3):568-73. PubMed ID: 2869139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
    Jackson EK; Herzer WA; Zimmerman JB; Branch RA; Oates JA; Gerkens JF
    J Pharmacol Exp Ther; 1981 Jan; 216(1):24-7. PubMed ID: 7005428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2.
    Spannhake EW; Levin JL; Hyman AL; Kadowitz PJ
    Prostaglandins; 1981 Feb; 21(2):267-75. PubMed ID: 7012934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.